Abstract
Since its invention in 1897, aspirin (ASA) has been the most widely used and cost-effective antiplatelet agent to prevent and treat atherosclerotic cardiovascular disease (ASCVD). We aimed to study the trends and expenditures associated with ASA use in the USA. We conducted a serial cross-sectional analysis using the Medical Expenditure Panel Survey data from January 2000 to December 2021, focusing on adults aged ≥ 40years. Total and out-of-pocket expenditures associated with ASA were estimated to 2021 US dollars (USD). Trends, demographics, and predictors of ASA use among patients with and without ASCVD were also evaluated. A total of 53million adults were identified during the study period. The number of ASA users increased from 2.9million to 6.6million with increased female (36.7%-49.7%; ptrend = 0.02) and African American (13%-18.9%; ptrend = 0.03) representation amongst all ASA users during the survey period. The use of low-dose ASA increased, while high-dose ASA declined significantly. Only 50% of all ASA users had known ASCVD. The most prevalent ASA users among patients with ASCVD were those aged ≥ 70years, while patients without ASCVD, it was the 50-69 age group. The total annual expenditure on ASA averaged approximately 60million USD, with 27.3million USD out-of-pocket. Total and low-dose (81mg) ASA use has increased, while high-dose (325mg) ASA has declined. ASA use for primary prevention has risen among adults aged 50-69years, and patients ≥ 70years continue to use ASA without known ASCVD. Further studies are needed to understand the implications of increased ASA use, especially among those without ASCVD.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call